IISc Bengaluru comes up with warm vaccine against current strains of SARS-CoV-2

According to IISc., while current vaccines are proven to be effective against most SARS-CoV-2 strains, their efficacy has declined due to rapid mutation by the virus.

A heat-tolerant vaccine developed by the Indian Institute of Science (IISc.) researchers is said to be effective against all current strains of SARS-CoV-2 besides having the potential to be quickly adapted for future variants as well.

According to IISc-Bengaluru, since the beginning of the COVID-19 pandemic, Prof. Raghavan Varadarajan from the institute’s Molecular Biophysics Unit (MBU) and collaborators have been working on developing a heat-tolerant vaccine that can offer protection against different strains of SARS-CoV-2 – both current and future variants. In a study published in npj Vaccines, they report the design of a synthetic antigen that can be manufactured as a potential COVID-19 vaccine candidate.

They showed that their vaccine is effective against all current strains of SARS-CoV-2, and can be quickly adapted for future variants as well.

According to IISc., while current vaccines are proven to be effective against most SARS-CoV-2 strains, their efficacy has declined due to rapid mutation by the virus. After analysing various proteins found in the virus, the researchers selected two parts of SARS-CoV-2’s spike protein – the S2 subunit and the Receptor Binding Domain (RBD) – for designing their vaccine candidate. The S2 subunit is highly conserved. It mutates much less than the S1 subunit, which is the target of most current vaccines. Scientists have also known that the RBD can provoke a strong immune response in the host. Therefore, the team created a hybrid protein called RS2 by combining these two components.

The researchers used mammalian cell lines to study the expression of the hybrid protein.

“The protein showed very high levels of expression, and I (initially) thought that the experiment was not working properly,” said Nidhi Mittal, PhD student at MBU and first author of the study.

The team then tested the effects of the protein in both mice and hamster models. They found that the hybrid protein triggered a strong immune response and provided better protection when compared to vaccines containing the whole spike protein.